LNSRNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

LENSAR, Inc.

LENSAR, Inc. designs, develops, and commercializes laser-based systems for cataract surgery and the management of corneal astigmatism. Its business combines sales of the ALLY System with recurring revenue from procedure licenses, leases, service contracts, and consumables, making it a medical-device platform tied to surgeon adoption and procedure volume.

Kysy yhtiöstä
Liikevaihto58,4milj. USD
+9,2 %v/v
Liikevoitto (EBIT)−24,6milj. USD
−130,5 %v/v
EBIT-marginaali−42,1%
−22,1 %-yks.v/v
Nettotulos−34,3milj. USD
−9,2 %v/v
Vapaa kassavirta−14,9milj. USD
−513,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−40−200204060milj. USD2020: 26 milj. USD2020: EBIT −19 milj. USD20202021: 34 milj. USD2021: EBIT −20 milj. USD20212022: 35 milj. USD2022: EBIT −20 milj. USD20222023: 42 milj. USD2023: EBIT −12 milj. USD20232024: 53 milj. USD2024: EBIT −11 milj. USD20242025: 58 milj. USD2025: EBIT −25 milj. USD202558−25
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: LENSAR, Inc.

Liiketoiminta

Osuus liikevaihdosta
Laser cataract surgery systems19 %

Capital equipment used by surgeons to perform laser-assisted cataract procedures.

Procedure licenses / consumables59 %

Recurring per-procedure licenses and related application revenue tied to system usage.

Leases13 %

Non-cancellable equipment leases that generate recurring lease revenue.

Service and warranties9 %

Extended warranty and maintenance services for installed systems.

Tuotteet

Raportoitu · osuus liikevaihdosta
88,9%11,1%FY2025100 %
  • Products88,9 %
  • Services11,1 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

LENSAR sells primarily to cataract surgeons, ophthalmology practices, and surgical centers that want laser-assisted tools for cataract treatment and astigmatism management. In the U.S. it uses a direct sales organization, while outside the U.S. it relies on independent distributors, so customer access and adoption depend heavily on clinical training, regulatory clearance, and distributor execution.

U.S. cataract surgeons and practices

Buy or lease ALLY systems and recurring procedure licenses for direct clinical use in the United States.

International distributors

Purchase systems and consumables for resale in their territories and are critical to market access outside the U.S.

Ambulatory surgery centers

Use the system for cataract procedures where workflow speed and reproducibility matter.

Surgeons using leased systems

Prefer leasing to reduce upfront capital spending while still accessing the platform.

Strategia

LENSAR is focused on expanding adoption of the ALLY System by building a larger U.S. sales and support organization and extending international reach through distributors. Its strategy also emphasizes recurring revenue from procedure licenses, leases, and service, which can make revenue more durable than one-time equipment sales.

Expand U.S. commercial organizationLyhyt aikaväli

More sales and clinical support personnel should improve adoption and customer retention.

Broaden international market accessKeskipitkä aikaväli

Distributor-led expansion can increase installed base and recurring procedure revenue outside the U.S.

Shift mix toward recurring revenueKeskipitkä aikaväli

Procedure licenses, leases, and service contracts can smooth revenue versus system sales.

Scale ALLY manufacturing and supply chainLyhyt aikaväli

Commercial success depends on delivering systems on time and at acceptable cost.

Maantiede

Q1/2026

The company is headquartered and manufactures in the United States, with production at its Orlando, Florida facility. Commercially, it sells directly in the U.S. and uses distributors in Germany, China, India, South Korea, and other international markets, making regulatory approvals and distributor performance central to growth.

USA73 %
Europe16 %
Asia11 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

The company depends on regulatory clearances, production execution, and distributor performance to convert product development into sales. It also faces concentration risk, competitive pressure from larger ophthalmology companies, and supply-chain constraints that can disrupt deliveries or delay market expansion.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Supply-chain and manufacturing disruption1Regulatory clearance and certification risk2Distributor concentration and dependence3Merger execution risk4Competitive pressure from larger ophthalmology players5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Supply-chain and manufacturing disruptionVaikutus: KorkeaTodennäköisyys: Korkea

    The company uses custom and single-source components with limited long-term supply agreements, so shortages can delay production and shipments.

    Kohdistuu: Orlando manufacturing and component sourcing

  2. Regulatory clearance and certification riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company cannot expand many markets without local approvals, which can delay commercialization and limit addressable demand.

    Kohdistuu: ALLY System and international expansion

  3. Distributor concentration and dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Outside the U.S. the company relies exclusively on independent distributors, so loss or underperformance of a distributor can quickly reduce revenue.

    KohdistuuGermanyChinaIndiaSouth KoreaOther international markets
  4. Merger execution riskVaikutus: KeskitasoTodennäköisyys: Korkea

    The pending Alcon transaction can create uncertainty, additional costs, and potential distraction from commercial execution.

    Kohdistuu: Corporate strategy and operations

  5. Competitive pressure from larger ophthalmology playersVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Competitors have greater resources, brand recognition, and broader product portfolios, which can make it harder to win placements and maintain pricing.

    Kohdistuu: Cataract surgery systems market

Kysy Clarifolta: LENSAR, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition across multiple streams

System sales, procedure licenses, lease revenue, and service revenue may be recognized differently, affecting quarterly comparability and recurring revenue quality.

Vaikutus: Revenue timing and mix

Lease accounting

Leased systems create recurring lease revenue and associated depreciation, which affects gross margin and asset utilization.

Vaikutus: Revenue, depreciation, and balance sheet assets

Warranty and service provisions

Extended warranties and maintenance obligations require estimates of future service costs.

Vaikutus: Cost of revenue and liabilities

Inventory reserves

The company holds component inventory and may record excess or obsolete charges if demand or supply changes.

Vaikutus: Gross margin and working capital

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

STAAR Surgical Company

STAA · Ophthalmic Goods

RxSight, Inc.

RXST · Ophthalmic Goods

Luminar Technologies, Inc.

Motor Vehicle Parts & Accessories

Kodiak Sciences Inc.

KOD · Biological Products, (No Diagnostic Substances)

Escalon Medical Corp

ESMC · Electromedical & Electrotherapeutic Apparatus

Sanara MedTech Inc.

SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies

Päivitetty: 24.9.2026

LENSAR, Inc. (LNSR) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo